Purple Biotech (PPBT) Liabilities and Shareholders Equity (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $14.4 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $14.4 million, down 59.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $105.4 million (down 26.69% YoY), and the FY2025 annual result was $17.6 million, down 52.56% from the prior year.
• Liabilities and Shareholders Equity eased to $14.4 million in Q1 2026 per PPBT's latest filing, from $17.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $66.3 million in Q1 2022 and troughed at $14.4 million in Q1 2026.
• A 5-year average of $42.4 million and a median of $39.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity gained 11.27% in 2025, then tumbled 59.5% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $54.6 million in 2022, then retreated by 18.89% to $44.3 million in 2023, then fell by 16.4% to $37.0 million in 2024, then sank by 52.56% to $17.6 million in 2025, then declined by 17.95% to $14.4 million in 2026.
• Business Quant data shows PPBT's Liabilities and Shareholders Equity at $14.4 million in Q1 2026, $17.6 million in Q4 2025, and $39.1 million in Q3 2025.